The US is working on rules for pharmaceutical companies investing in China that would likely preserve their ability to strike most licensing deals for Chinese drugs, according to three people who have been briefed on ​the process. That would mark a departure from the Trump administration’s tightening of business with China for other industries under new national security legislation, and would be looser than restrictions sought ‌by some lawmakers. The rules – being drafted by the US Treasury Department – are likely to allow US pharmaceutical companies to invest in promising new drugs being developed by Chinese companies as long as they are not related to pathogens or biotechnology that could be weaponized, the sources said.

Full report : The US is working on rules for pharmaceutical companies invest in China.